Clinical Trial Update: Simvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory Multiple Myeloma [EARLY_Phase 1]

View source ↗

Summary

An early-phase study evaluating simvastatin to overcome chemotherapy resistance in relapsed or refractory multiple myeloma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• SIMVASTATIN (SIMVASTATIN)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | EARLY_Phase 1 | Status: WITHDRAWN